GBIO
Price
$6.00
Change
+$0.28 (+4.90%)
Updated
Sep 26 closing price
Capitalization
40.41M
39 days until earnings call
OVID
Price
$1.73
Change
+$0.32 (+22.70%)
Updated
Sep 26 closing price
Capitalization
123.02M
46 days until earnings call
Interact to see
Advertisement

GBIO vs OVID

Header iconGBIO vs OVID Comparison
Open Charts GBIO vs OVIDBanner chart's image
Generation Bio
Price$6.00
Change+$0.28 (+4.90%)
Volume$89.44K
Capitalization40.41M
Ovid Therapeutics
Price$1.73
Change+$0.32 (+22.70%)
Volume$6.53M
Capitalization123.02M
GBIO vs OVID Comparison Chart in %
Loading...
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GBIO vs. OVID commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GBIO is a Hold and OVID is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (GBIO: $6.00 vs. OVID: $1.73)
Brand notoriety: GBIO and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GBIO: 23% vs. OVID: 383%
Market capitalization -- GBIO: $40.41M vs. OVID: $123.02M
GBIO [@Biotechnology] is valued at $40.41M. OVID’s [@Biotechnology] market capitalization is $123.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GBIO’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • GBIO’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, OVID is a better buy in the long-term than GBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GBIO’s TA Score shows that 3 TA indicator(s) are bullish while OVID’s TA Score has 5 bullish TA indicator(s).

  • GBIO’s TA Score: 3 bullish, 3 bearish.
  • OVID’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OVID is a better buy in the short-term than GBIO.

Price Growth

GBIO (@Biotechnology) experienced а +4.35% price change this week, while OVID (@Biotechnology) price change was +42.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

GBIO is expected to report earnings on Nov 05, 2025.

OVID is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OVID($123M) has a higher market cap than GBIO($40.4M). OVID YTD gains are higher at: 85.284 vs. GBIO (-43.396). OVID has higher annual earnings (EBITDA): -41.01M vs. GBIO (-69.92M). GBIO has more cash in the bank: 141M vs. OVID (38.3M). OVID has less debt than GBIO: OVID (14.1M) vs GBIO (85.3M). GBIO has higher revenues than OVID: GBIO (21.2M) vs OVID (6.65M).
GBIOOVIDGBIO / OVID
Capitalization40.4M123M33%
EBITDA-69.92M-41.01M171%
Gain YTD-43.39685.284-51%
P/E RatioN/AN/A-
Revenue21.2M6.65M319%
Total Cash141M38.3M368%
Total Debt85.3M14.1M605%
FUNDAMENTALS RATINGS
OVID: Fundamental Ratings
OVID
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
93
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GBIOOVID
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 13 days ago
89%
Bearish Trend 23 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
GBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCAB0.670.04
+6.22%
BioAtla
ARW120.922.08
+1.75%
Arrow Electronics
AVNW22.540.11
+0.49%
Aviat Networks
SPGI487.182.24
+0.46%
S&P Global
QCRH76.75-1.16
-1.49%
QCR Holdings

GBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with CABA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GBIO
1D Price
Change %
GBIO100%
+4.90%
CABA - GBIO
46%
Loosely correlated
+2.16%
SYRE - GBIO
44%
Loosely correlated
+4.04%
MGNX - GBIO
43%
Loosely correlated
+4.85%
IDYA - GBIO
42%
Loosely correlated
+4.44%
OVID - GBIO
41%
Loosely correlated
+22.70%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+22.70%
JBIO - OVID
79%
Closely correlated
+5.21%
ARCT - OVID
45%
Loosely correlated
+9.16%
STOK - OVID
42%
Loosely correlated
+5.19%
GBIO - OVID
41%
Loosely correlated
+4.90%
MGNX - OVID
41%
Loosely correlated
+4.85%
More